NSG Bio and Chiesi launch a startup initiative focused on respiratory and neonatal care. See how it could help transform research into real treatments.

NSG Bio and Chiesi launch a new initiative aimed at giving early-stage biotech startups the support they need to move promising research closer to helping patients. Called The Impulse initiative, the program is part of NSG Bio Tomorrow and focuses on startups developing solutions for respiratory and neonatal care.

Building more than just laboratory space

Backed by Chiesi Group, the initiative will provide one selected startup with a year-long NSG Bio membership, a dedicated laboratory bench in Singapore, and access to research facilities, industry experts, and a growing biotech community. The goal is to help young companies strengthen their proof-of-concept research while connecting them with the networks needed to bring innovative healthcare solutions to market.

The program is open to startups working on advanced technologies such as gene therapy, cell therapy, gene editing, regenerative tissue engineering, lung-targeted drug delivery, programmable living systems, and small-molecule treatments. These are areas that hold strong potential for improving care for chronic respiratory diseases and conditions affecting newborn babies.

"Biotech companies need more than lab space. They need access, momentum, and the right ecosystem around them," said Hasyim Sim, Co-Founder and Chief Operating Officer of NSG Bio. "Through NSG Bio Tomorrow, we are building initiatives that help promising startups connect with partners, unlock opportunities, and move their science forward."

Why does this matter for biotech startups?

One of the biggest challenges for early biotech companies is access to expensive research infrastructure and experienced industry partners. While scientific talent is essential, startups also need funding opportunities, collaboration, mentorship, and modern laboratory facilities to transform research into real medical innovations.

The selected company will benefit from NSG Bio's shared laboratories, workspaces, meeting facilities, and connections with researchers, investors, and healthcare industry leaders. Chiesi Group believes this collaborative approach can help accelerate scientific discoveries that improve patient care.

Applications for the program opened on 22 July 2026, with finalists set to present their ideas during a virtual pitch event before the winning startup is announced.

As Business Fortune observes, Singapore continues strengthening its position as one of Asia's leading biotech hubs and initiatives like this could play an important role in nurturing the next generation of healthcare innovators. By bringing together science, infrastructure, and industry expertise, the partnership may help transform today's laboratory discoveries into tomorrow's life-changing treatments.

 

FAQs

What is The Impulse initiative?

It is a startup support program launched by NSG Bio Tomorrow with backing from Chiesi Group to help early-stage biotech companies advance their research.

Which startups can apply?

The initiative targets startups developing technologies for respiratory diseases and neonatal care, including gene therapy, cell therapy, regenerative medicine, and related biotech innovations.

What support will the selected startup receive?

The winning startup will receive one year of NSG Bio membership, a dedicated laboratory bench, access to research infrastructure, and connections to industry experts and investors.

Why is Singapore an important location for this program?

Singapore has become a growing biotech and life sciences hub in Asia, offering strong research facilities, investment opportunities, and collaboration between academia and industry.

When did applications open?

Applications officially opened on 22 July 2026, and shortlisted startups will participate in a virtual pitch event before the final selection.